632 related articles for article (PubMed ID: 18190908)
1. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
2. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
Bruins Slot LA; Lestienne F; Grevoz-Barret C; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2009 Oct; 620(1-3):27-35. PubMed ID: 19695244
[TBL] [Abstract][Full Text] [Related]
5. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
[TBL] [Abstract][Full Text] [Related]
6. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
[TBL] [Abstract][Full Text] [Related]
7. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
Bruins Slot LA; Palmier C; Tardif S; Cussac D
Neuropharmacology; 2007 Aug; 53(2):232-41. PubMed ID: 17588617
[TBL] [Abstract][Full Text] [Related]
8. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
9. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
Newman-Tancredi A; Assié MB; Leduc N; Ormière AM; Danty N; Cosi C
Int J Neuropsychopharmacol; 2005 Sep; 8(3):341-56. PubMed ID: 15707540
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
van den Buuse M; Gogos A
J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
[TBL] [Abstract][Full Text] [Related]
11. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
13. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
14. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Bruins Slot LA; Kleven MS; Newman-Tancredi A
Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
[TBL] [Abstract][Full Text] [Related]
15. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
[TBL] [Abstract][Full Text] [Related]
16. Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Cussac D; Duqueyroix D; Newman-Tancredi A; Millan MJ
Psychopharmacology (Berl); 2002 Jul; 162(2):168-77. PubMed ID: 12110994
[TBL] [Abstract][Full Text] [Related]
17. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
18. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
[TBL] [Abstract][Full Text] [Related]
19. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
Gogos A; Kwek P; Chavez C; van den Buuse M
J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
[TBL] [Abstract][Full Text] [Related]
20. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
